Compare Charles River Laboratories Intl. Inc (CRL) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs EPAM Systems Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while EPAM Systems Inc trades at $112.92 (market cap $5.87B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.4× EPAM Systems Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and EPAM Systems Inc for 37 Days on average.
| CRL | EPAM | |
|---|---|---|
Market Cap | $14.23B | $5.87B |
Volume | 1,176,885 | 847,420 |
Sector | Health | Technology |
52-Week High | $310.77 | $221.40 |
52-Week Low | $149.93 | $76.04 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $17.06B | $5.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
EPAM Systems trades at $113.24, up 4.54% today, reflecting strong momentum. The stock shows a bullish technical trend, trading near resistance at $115. Fundamentally, EPAM reported Q2 2026 EPS of $3.38, beating estimates, with revenue reaching $5.46B in 2025. Recent news highlights a partnership with Wiz for cloud security and activist investor Engine Capital urging share buybacks, signaling confidence in undervaluation.
The outlook is positive, supported by a consensus price target of $119 and strong analyst buy ratings (59.46%). However, risks include slower North American growth and AI disruption to legacy services. The stock presents a value opportunity with a P/E of 15.45, but investors should monitor execution on AI-native revenue growth and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
